Skip to main content
Xiangxue Pharmaceutical Co., Ltd. logo

Xiangxue Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300147 ISIN · CNE100000Y92 LEI · 3003000D8UMO4KQ95B57 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,280 across all filing types
Latest filing 2025-04-28 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 300147

About Xiangxue Pharmaceutical Co., Ltd.

https://www.xphcn.com

Xiangxue Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of modern Traditional Chinese Medicine (TCM), chemical drugs, and biological products. The company is recognized for its focus on the modernization of TCM, utilizing advanced technology to standardize and enhance traditional formulas. Its flagship products include anti-viral oral liquids and Banlan'gen granules, which are widely used for respiratory health. Beyond traditional treatments, the company has expanded into high-tech biomedical fields, including precision medicine and adoptive cell therapy, specifically TCR-T cell technology for cancer treatment. Xiangxue operates a comprehensive value chain encompassing medicinal herb cultivation, pharmaceutical manufacturing, and healthcare services. By integrating digital technology with pharmaceutical expertise, the company aims to provide integrated health solutions and innovative therapies.

Recent filings

Filing Released Lang Actions
关于2024年度不进行利润分配的专项说明
Notice of Dividend Amount Classification · 95% confidence The document is a formal announcement from 广州市香雪制药股份有限公司 regarding the company's 2024 profit distribution plan, specifically stating that no profit distribution (dividends) will be made for the year 2024. It includes detailed financial figures such as net profit, retained earnings, and reasons for not distributing dividends. The document also contains opinions from the independent directors, audit committee, board of directors, and supervisory board, all supporting the no-dividend proposal to be submitted to the shareholders' meeting. The content focuses on dividend policy and profit distribution rather than presenting a full financial report or earnings release. The document length is 2119 characters, which is relatively short and primarily an announcement of the dividend decision rather than a comprehensive report. Therefore, it fits best under the category of Notice of Dividend Amount (DIV), as it announces the dividend decision and related details for shareholders.
2025-04-28 Chinese
关于2023年度审计报告保留意见涉及事项影响已消除的专项说明
Audit Report / Information Classification · 95% confidence The document is a special explanation regarding the elimination of the impact of reserved opinions in the 2023 annual audit report of Guangzhou Xiangxue Pharmaceutical Co., Ltd. It discusses the audit report issued by the auditor with a reserved opinion and details the company's actions to address the issues raised. The document is not the audit report itself but a statement about the resolution of issues related to the audit report's reserved opinions. The document length is short (1346 characters) and it serves as an announcement or explanation related to the audit report rather than the full audit report. Therefore, it fits best under Audit Report / Information (AR) as it provides information specifically about the audit report's reserved opinions and their resolution, rather than being a full annual report or a simple announcement of report publication. FY 2023
2025-04-28 Chinese
2024年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as "广州市香雪制药股份有限公司2024 年年度报告摘要" which translates to "Guangzhou Xiangxue Pharmaceutical Co., Ltd. 2024 Annual Report Summary." It contains detailed financial data for the year 2024, including total assets, net profit, revenue, quarterly financial data, business overview, research projects, shareholder information, and audit opinions. The document is over 10,000 characters, indicating it is a substantive report rather than a brief announcement. It includes audited financial statements and comprehensive business and financial information typical of an annual report. Therefore, this document is classified as an Annual Report (10-K). FY 2024
2025-04-28 Chinese
独立董事2024年度述职报告（陶剑虹）
Board/Management Information Classification · 95% confidence The document is an Independent Director's 2024 Annual Work Report for 广州市香雪制药股份有限公司. It details the director's duties, attendance at board and shareholder meetings, committee participation, communication with auditors, oversight of company operations, and key issues addressed during the year. It references compliance with laws and regulations, review of financial reports, and governance activities. The content is a detailed management and governance report by an independent director rather than a financial report, earnings release, or announcement. It does not contain financial statements or earnings data but focuses on board and governance matters. Therefore, the document fits best under Board/Management Information (MANG). The document length (5984 characters) and detailed content support this classification with high confidence.
2025-04-28 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Guangzhou Xiangxue Pharmaceutical Co., Ltd. It details the approval of various reports and proposals related to the 2024 fiscal year, including the 2024 Supervisory Board Work Report, 2024 Financial Final Accounts Report, 2024 Audit Report and Financial Statements, 2024 Annual Report, profit distribution plan, internal control self-evaluation report, and other related matters. The document repeatedly states that these reports are disclosed on an external platform (巨潮资讯网) and that the resolutions will be submitted to the 2024 Annual General Meeting for approval. The document itself does not contain the full financial statements or detailed financial data but rather summarizes the resolutions passed by the Supervisory Board. The document length is 2857 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an official announcement of Supervisory Board meeting resolutions and approvals related to annual reports and financial statements, but it is not the full Annual Report (10-K) or Audit Report (AR) itself.
2025-04-28 Chinese
2024年度监事会工作报告
Board/Management Information Classification · 95% confidence The document is titled as the "2024年度监事会工作报告" (2024 Supervisory Board Work Report) of 广州市香雪制药股份有限公司. It details the supervisory board's activities, oversight of company management, financial supervision, internal control evaluations, and related governance matters for the year 2024. The content includes detailed supervisory opinions on financial reports, audit reports, internal controls, related party transactions, and plans for 2025. The document is a comprehensive report from the supervisory board rather than an announcement or a brief summary. It does not fit the Annual Report (10-K) category as it is specifically a supervisory board report, nor is it a Management Report (MDA) or Audit Report (AR) standalone. It is a detailed governance-related report focusing on supervisory activities and oversight, which aligns best with Board/Management Information (MANG) as it relates to board-level oversight and governance activities. The document length is 3617 characters, which is substantial but not extremely long, consistent with a detailed board report. Therefore, the most appropriate classification is MANG with high confidence.
2025-04-28 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.